Long-Term Follow-up Observation of the Safety, Immunogenicity, and Effectiveness of Gardasil™ in Adult Women

Vaccine-Relevant Human Papillomavirus (HPV) Infections and Future Acquisition of High-Risk HPV Types in Men

(2012) Anne F. Rositch et al.   JOURNAL OF INFECTIOUS DISEASES

End-of-study safety, immunogenicity and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age

(2011) X Castellsagué et al.   BRITISH JOURNAL OF CANCER

The humoral response to Gardasil over four years as defined by Total IgG and competitive Luminex immunoassay

(2011) Darron R. Brown et al.   Human vaccines & immunotherapeutics

Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males

(2011) Anna R. Giuliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evolution of type-specific immunoassays to evaluate the functional immune response to GARDASIL®, a vaccine for Human Papillomavirus types 16, 18, 6, and 11

(2010) Judith F. Smith et al.   Human vaccines & immunotherapeutics

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives

(2009) Xavier Castellsagué et al.   GYNECOLOGIC ONCOLOGY

Immunogenicity Testing in Human Papillomavirus Virus‐Like‐Particle Vaccine Trials

(2009) John T. Schiller et al.   JOURNAL OF INFECTIOUS DISEASES

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial

(2009) Nubia Muñoz et al.   LANCET